Respiratory Medicine and Research最新文献

{"title":"Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD","authors":"Bess M. Flashner ,&nbsp;Ryosuke Imai ,&nbsp;Andrew J. Synn ,&nbsp;Julia K. Munchel ,&nbsp;Lida P. Hariri ,&nbsp;Fiona K. Gibbons ,&nbsp;Sydney B. Montesi ,&nbsp;Barry S. Shea ,&nbsp;Mary B. Rice ,&nbsp;Rene S. Bermea ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2025.101176","DOIUrl":"10.1016/j.resmer.2025.101176","url":null,"abstract":"<div><h3>Background</h3><div>Evaluation for interstitial lung disease (ILD) often involves sending a myositis panel that includes myositis-associated and myositis-specific antibodies (MAA and MSA respectively) such as anti-Mi-2. Little is known about anti-Mi-2 positive ILD. We sought to determine the typical presentation and prognosis of anti-Mi-2 positive ILD.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of patients in two ILD referral centers in Boston, MA with a positive anti-Mi-2 antibody between 2012 and 2024. Patients were identified by query of the medical record for patients with anti-Mi-2, and we included those with ILD on chest computed tomography (CT). We conducted survival analyses for ILD progression-free and overall survival using Kaplan-Meier curves and log-rank tests. Additionally, a Cox proportional-hazards model was employed, adjusting for age, gender, baseline forced vital capacity, and immunosuppressant use to calculate hazard ratios. The comparator group included patients who were followed longitudinally in the ILD clinic who were anti-Mi-2 negative but positive for other MSAs.</div></div><div><h3>Results</h3><div>Fifty-eight patients were identified. Half (52 %) were female with mean age 67 years (SD 13 years). The majority had dyspnea and/or cough, and a quarter of patients required oxygen upon presentation. Six (10 %) had PM/DM that pre-dated their ILD diagnosis. Other autoantibody positivity was common; one-third-of patients (<em>n</em> = 19, 33 %) were positive for anti-Mi-2 alone without positivity for other MSAs or MAAs. Clinical follow up data were available for 52 patients for a median follow up of 24 months (range &lt;1 month-10 years). PFT progression was seen in 67 % and radiologic progression was seen in over a third. Half received immunosuppression (55 %), with 19 % requiring multiple immunosuppressives. During follow up, 21 % had acute exacerbation of ILD or death. Progression-free and overall survival were not significantly different among anti-Mi-2 positive ILD <em>versus</em> anti-Mi-2 negative, MSA positive ILD patients regardless of anti-Mi-2 positivity alone or in combination with other autoantibodies.</div></div><div><h3>Conclusions</h3><div>This series of 58 patients is the largest anti-Mi-2 positive ILD cohort to date. Concurrent positivity with other autoantibodies associated with ILD was common. Anti-Mi-2 positive ILD was associated with similar outcomes to those with other MSAs. Larger studies are needed to better characterize patients with Mi-2 positive ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101176"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-synthetase syndrome: A focus on interstitial lung disease as a diagnostic criteria","authors":"Jessica A. Peterson ,&nbsp;Caroline Cook ,&nbsp;Hanzhi Gao ,&nbsp;Raju Reddy ,&nbsp;Bruno Hochhegger ,&nbsp;Diana Gomez-Manjarres ,&nbsp;Faye Pais","doi":"10.1016/j.resmer.2025.101190","DOIUrl":"10.1016/j.resmer.2025.101190","url":null,"abstract":"<div><h3>Background</h3><div>Anti-synthetase syndrome (ASyS) is an autoimmune disorder with clinical manifestations that often include interstitial lung disease (ILD), myositis, and arthritis. Although it shares features with other idiopathic inflammatory myopathies, ILD is more prevalent and often more severe in this syndrome. The aim of this study was to compare Connors and Solomon diagnostic criteria for ASyS and investigated whether the presence of no additional symptoms, one additional symptom, or two or more symptoms, in addition to ILD and relevant antibodies, would indicate a worse prognosis.</div></div><div><h3>Methods</h3><div>This retrospective single-center study examined patients who were previously diagnosed with ASyS based on Connors or Solomon criteria and were further categorized using the 273rd ENMC International workshop criteria and post-hoc. The patients were then stratified based upon how many “defining” signs and symptoms that they had in addition to ILD and antibodies. Demographic characteristics, pulmonary function tests (PFT), chest CT’s—along with clinical outcomes were assessed.</div></div><div><h3>Results</h3><div>No differences in demographic factors and PFT’s were found between those who were diagnosed using Solomons versus Connors criteria. No differences in demographic, PFT’s and chest CT’s between those with ILD and antibodies only, with 1 additional criteria, and with 2+ additional criteria groups, although those with two or more additional criteria had a longer duration since diagnosis.</div></div><div><h3>Discussion</h3><div>Key findings from the study suggest that there are no differences in diagnostic outcomes, therapeutic interventions, or mortality rates when using different criteria to diagnose ASyS. This study suggests a reevaluation of diagnostic criteria for ASyS to prioritize ILD and relevant antibodies rather than a focus of additional criteria, supporting the new ASyS defining criteria from 273rd ENMC International Workshop (2024).</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101190"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does occupational exposure affect the surgical management of patients with non-small cell lung cancer? A single-center retrospective experience","authors":"Matthieu Thumerel ,&nbsp;Camille Carles ,&nbsp;Hugues Begueret ,&nbsp;Quentin Thomas ,&nbsp;Jacques Jougon ,&nbsp;Carine Audoin ,&nbsp;Jean-François Bernaudin ,&nbsp;Patrick Brochard ,&nbsp;Yaniss Belaroussi","doi":"10.1016/j.resmer.2025.101183","DOIUrl":"10.1016/j.resmer.2025.101183","url":null,"abstract":"<div><h3>Objective</h3><div>Non-small-cell lung cancer (NSCLC) remains a major public health concern, with tobacco and environmental exposures to carcinogens (such as asbestos, radon, and silica) recognized as major risk factors. This study investigates the impact of occupational exposure, particularly to crystalline silica on peri‑ and postoperative outcomes in patients undergoing surgery for NSCLC.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 251 patients who underwent lobectomy or segmentectomy between 2018 and 2021, with occupational exposure data collected postoperatively.</div></div><div><h3>Results</h3><div>Our findings suggest that patients with occupational exposure, particularly to silica, asbestos, or multiple carcinogens, have more complex surgical courses, including longer operative times, higher rates of conversion from minimally invasive to open surgery, and increased postoperative complications (Clavien-Dindo grade II or higher). Preoperative lymph node staging was less accurate in exposed patients, in part because of inflammatory changes such as fibro-hyaline lesions, which can cause false-positive PET/CT findings.</div></div><div><h3>Conclusions</h3><div>The study highlights the need for tailored surgical strategies and accurate lymph node staging in exposed individuals. Future research should focus on prospective studies to refine perioperative management and explore the biological mechanisms driving these complications.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101183"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does size matter: Diagnostic yield and significance of small intrathoracic lymph nodes sampled on EBUS-TBNA","authors":"Lorraine Thong,&nbsp;Mohammed Mitha,&nbsp;David Breen","doi":"10.1016/j.resmer.2025.101198","DOIUrl":"10.1016/j.resmer.2025.101198","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101198"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchiectasis in France: data on disease characteristics in 630 patients from the European Bronchiectasis registry (EMBARC)","authors":"Pierre-Régis Burgel ,&nbsp;Anne Bergeron ,&nbsp;Bernard Maitre ,&nbsp;Claire Andrejak ,&nbsp;Cristina Audoly ,&nbsp;Jean-François Boitiaux ,&nbsp;Boubou Camara ,&nbsp;Nathalie Coolen-Allou ,&nbsp;Benoit Douvry ,&nbsp;Gérard Chatté ,&nbsp;Annlyse Fanton ,&nbsp;Sylvie Leroy ,&nbsp;Clémence Martin ,&nbsp;Karine Michaux ,&nbsp;Annabelle Payet ,&nbsp;Hervé Pegliasco ,&nbsp;Frédéric Schlemmer ,&nbsp;Guillaume Vignal ,&nbsp;Agnès Duchange ,&nbsp;Espérie Burnet ,&nbsp;Marlène Murris-Espin","doi":"10.1016/j.resmer.2025.101199","DOIUrl":"10.1016/j.resmer.2025.101199","url":null,"abstract":"<div><h3>Background</h3><div>Little is known about the characteristics of adults with bronchiectasis in France.</div></div><div><h3>Methods</h3><div>A descriptive cross-sectional study was conducted to describe the characteristics of adults (≥18 years) with clinically-significant bronchiectasis, diagnosed on a combination of respiratory symptoms and CT scan findings, and followed in 18 participating centers. Data on, etiology, lung function, symptoms, microbiology, treatments and quality of life were collected.</div></div><div><h3>Results</h3><div>Between January 2016 and July 2022, 630 adults (females: 66 %; ≥55 years: 73.8 %) were included. Idiopathic and post-infective causes represented 33.0 % and 37.1 % respectively; COPD and asthma, which were present in 15.6 % and 23.6 % of subjects, were considered as causes of bronchiectasis in only 3.8 % and 2.9 %, respectively. Only 25 % had normal spirometry and 7.3 % required long-term oxygen therapy. Daily sputum production was present in 78.1 % and 29.0 % had a modified Medical Research Council (mMRC) dyspnea score ≥2. Positive bacterial sputum culture was found in 77.8 % of those with sputum samples (<em>n</em> = 455); including 157 (34.5 %) positive for <em>Pseudomonas aeruginosa</em> within the past year. During the year prior to study entry, 75.4 % of patients reported at least one respiratory exacerbation, 33.8 % had at least one hospitalization and 24.5 % received outpatient parenteral antimicrobial therapy (OPAT). Using the bronchiectasis severity index 26.0 %, 36.4 % and 37.6 % were considered as having mild, moderate and severe disease, respectively.</div></div><div><h3>Conclusion</h3><div>In France, adults with bronchiectasis experience significant disease burden. Respiratory exacerbations are responsible for healthcare utilization and their prevention may require specialized multidisciplinary care and the development of novel therapeutic interventions.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101199"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of systemic lupus erythematosus in patients with interstitial pneumonia with autoimmune features using two different sets of criteria","authors":"Gabriela Martinez-Zayas ,&nbsp;David Karp ,&nbsp;Traci N. Adams ,&nbsp;Elena K. Joerns","doi":"10.1016/j.resmer.2025.101206","DOIUrl":"10.1016/j.resmer.2025.101206","url":null,"abstract":"<div><h3>Objective</h3><div>Interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease and autoimmunity who do not meet classification criteria for a systemic autoimmune rheumatic disease, including systemic lupus erythematosus (SLE). We aimed to determine whether the criteria developed by the European Alliance of Association of Rheumatology and American College of Rheumatology (EULAR/ACR) would classify more patients with IPAF as SLE, than those developed by the Systemic Lupus International Collaborating Clinics (SLICC). Increasing the recognition of SLE among patients with IPAF may affect therapy.</div></div><div><h3>Methods</h3><div>This observational, retrospective, single-center cohort study included consecutive patients initially classified as having IPAF between December 2005-August 2019. We reviewed patients’ charts to assess whether more patients met SLE criteria by SLICC or EULAR/ACR methodology. Fisher’s exact test assessed the significance of the difference in the proportion of patients classified by the two criteria.</div></div><div><h3>Results</h3><div>We included 201 patients initially classified as IPAF. Twelve were identified as SLE by SLICC criteria and 23 by EULAR/ACR criteria. All but three patients with lymphopenia who met SLE criteria by SLICC also met it by EULAR/ACR. The difference in the proportion of IPAF patients meeting SLE criteria by the two methods was statistically significant (<em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Patients with IPAF were classified as SLE more frequently using EULAR/ACR criteria than by SLICC criteria. The EULAR/ACR criteria may be superior for SLE classification in patients with ILD. Patients with IPAF and SLE features should undergo full work-up to evaluate for SLE classification as it may affect therapy.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101206"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute hemodynamic response to inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease: a case highlighting unresolved questions","authors":"Marianne Riou ,&nbsp;Matthieu Canuet ,&nbsp;Sandrine Hirschi ,&nbsp;Ségolène Turquier ,&nbsp;David Montani","doi":"10.1016/j.resmer.2025.101210","DOIUrl":"10.1016/j.resmer.2025.101210","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101210"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Remdesivir on long-term outcomes in lung transplant recipients with SARS-CoV-2 infection: a retrospective cohort analysis.","authors":"Damiana-Maria Vulturar, Gaëlle Dauriat, Anne Gigandon, Pauline Pradère, Pierre Gazengel, Samuel Dolidon, Chahine Medraoui, Amir Hanna, Adrian Crutu, Liviu-Stefan Moaca, Laurène Cachera, Delphine Mitilian, Dominique Fabre, Elie Fadel, Olaf Mercier, Alban Le Monnier, Jérôme Le Pavec, Benoît Pilmis","doi":"10.1016/j.resmer.2025.101192","DOIUrl":"10.1016/j.resmer.2025.101192","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has presented considerable challenges for lung transplant (LTx) recipients, a population inherently at high risk for severe complications. Although early data from the pandemic indicated worrisome outcomes for these patients, understanding the current context of SARS-CoV-2 infections is essential to inform ongoing management strategies. The efficacy of anti-viral treatments, including Remdesivir (RDV), remains uncertain. This study aims to evaluate the effect of RDV on clinical outcomes in LTx recipients infected with SARS CoV-2, primarily those with a clinically significant disease course.</p><p><strong>Methods: </strong>A single-center retrospective cohort study was conducted, including LTx recipients with confirmed SARS-CoV-2 infection diagnosed between January 2022 and December 2023. Patients were classified as treated with RDV if they received at least three consecutive days of therapy, typically initiated in the context of symptomatic infection with increased oxygen requirements (RDV group). The primary outcome was all-cause mortality. Secondary outcomes were ICU admission, longitudinal changes in lung function, at 3-, 6-, and 12-months post-infection, incidence of COVID-19-associated pulmonary aspergillosis (CAPA) and bacterial co-infections. A multivariable logistic regression model was used to control for cofounding factors.</p><p><strong>Results: </strong>Among the 130 LTx infected with SARS CoV-2, 61% (80/130) received at least 3 days of RDV. All cause of mortality was lower in the RDV group (4% 2/50) compared to the non-RDV group (15%, 12/80) (p= 0.05). Non-RDV group experienced a significant decline in forced expiratory volume in 1 second (FEV1) at 3 months post-infection compared to those in the RDV group (6% vs 3%, p = 0.04). ICU admission rates, bacterial coinfection, and CAPA were similar between groups.</p><p><strong>Conclusion: </strong>RDV treatment appears to improve survival and may mitigate the long-term deterioration of lung function in lung transplant recipients infected with SARS CoV-2. These findings underscore the potential of RDV as a beneficial therapy in this high-risk population and highlight the need for further investigation in larger studies.</p>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"101192"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute effects of fan therapy on exercise-induced breathlessness in healthy adults and people living with chronic respiratory disease: A systematic review","authors":"Julien Da Purificaçao ,&nbsp;Clémence Pierret ,&nbsp;Tristan Bonnevie ,&nbsp;William Poncin","doi":"10.1016/j.resmer.2025.101172","DOIUrl":"10.1016/j.resmer.2025.101172","url":null,"abstract":"<div><h3>Background</h3><div>Exercise-induced breathlessness is a common complaint in the general population and a highly prevalent symptom in adults living with chronic diseases, often acting as an important barrier to engaging in physical activity. Fan therapy can reduce breathlessness at rest, yet its acute effects during exercise have not been systematically explored.</div></div><div><h3>Methods</h3><div>A literature search encompassing three electronic databases (PubMed, Scopus, Embase) from inception to January 2025 was conducted to identify randomized controlled trials comparing fan therapy during and after an acute exercise bout to a control condition, on dyspnea and exercise capacity. Relevant conference abstracts were considered. Risk of bias was assessed via the Physiotherapy Evidence Database scale. The PRISMA guidelines were followed.</div></div><div><h3>Results</h3><div>A total of six studies, including one conference abstract, met eligibility criteria. Five records involved 79 adults with chronic respiratory disease, all presenting a respiratory disease, and the remaining record included 10 healthy individuals. The results were generally consistent, showing that fan therapy significantly reduces exercise-induced breathlessness (<em>n</em> = 2 studies), decreases breathlessness during recovery (<em>n</em> = 5), and enhances exercise capacity (<em>n</em> = 2). The methodological quality was good for half or retrieved studies and poor-to-fair in the other half.</div></div><div><h3>Conclusion</h3><div>Fan therapy might relieve dyspnea and improve exercise capacity during and after an acute bout of exercise in patients with chronic respiratory disease. Future high-quality research should confirm these findings and consider assessing fan therapy effects in other populations. PROSPERO number: CRD42023475117</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101172"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing sleep apnoea burden in the elderly in Finland from 1996 to 2018: A national registry study","authors":"Hannele Hasala ,&nbsp;Tiina Mattila ,&nbsp;Hanna-Riikka Kreivi ,&nbsp;Heidi Avellan-Hietanen ,&nbsp;Tuula Vasankari ,&nbsp;Fredrik Herse ,&nbsp;Riikka-Leena Leskelä ,&nbsp;Sanna Toppila-Salmi ,&nbsp;Marina Erhola ,&nbsp;Tuija Jääskeläinen ,&nbsp;Tari Haahtela","doi":"10.1016/j.resmer.2025.101201","DOIUrl":"10.1016/j.resmer.2025.101201","url":null,"abstract":"<div><h3>Background</h3><div>In many countries, obstructive sleep apnoea is causing an increased burden on healthcare. In Finland (population 5,5 million), the diagnoses of the condition have raised 7-fold from 1996 to 2018. Here, we present register-based data on sleep apnoea in the elderly Finnish people (aged ≥ 60 years) during the 23-year period.</div></div><div><h3>Methods</h3><div>Two cohorts were explored. The first cohort included all Finns who used public health services during the 23-year period. The data was collected from the Register for Health Care, Statistics Finland. The second cohort consisted of patients treated in the respiratory outpatient clinics from 2010 to 2019 in Tampere and Helsinki University Hospitals with a population of about 1,3 million.</div></div><div><h3>Results</h3><div>In people aged 60–69 years, the diagnoses of sleep apnoea per 100 000 persons have increased 9-fold, from 0.26 % (1996) to 2.3 % (2018). In those aged ≥ 70 years, the increase has been 23-fold, from 0.06 % to 1.4 %. Obesity is a growing risk factor. During the follow up, the direct healthcare costs of sleep apnoea increased from about €1 million (1996) to nearly €16 million (2018). The cost increase was explained by the mounting outpatient care costs with CPAP-treatment (Continuous Positive Airway Pressure).</div></div><div><h3>Conclusions</h3><div>In Finland, the prevalence and costs of diagnosed sleep apnoea and CPAP treatment have been in alarming increase in the elderly. This reflects improved awareness and diagnostics, but a risk of over diagnostics and over treatment is obvious. CPAP-treatment must be better targeted to those in true need.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101201"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144911893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}